ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SUMM Summit Therapeutics Plc

20.50
0.00 (0.00%)
Last Updated: 00:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Summit Therapeutics Plc LSE:SUMM London Ordinary Share GB00BN40HZ01 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 20.50 18.00 23.00 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Summit Therapeutics plc Summit Therapeutics Plc : Miscellaneous

16/11/2017 7:00am

UK Regulatory


 
TIDMSUMM 
 
   Summit Therapeutics plc 
 
   ("Summit" or the "Company") 
 
   SUMMIT APPOINTS PANMURE GORDON AS JOINT BROKER 
 
   Oxford, UK, 16 November 2017- Summit Therapeutics plc (NASDAQ: SMMT, 
AIM: SUMM) the drug discovery and development company advancing 
therapies for Duchenne muscular dystrophy and Clostridium difficile 
infection, announces the appointment of Panmure Gordon as joint broker 
with immediate effect to act alongside N+1 Singer. 
 
   About Summit Therapeutics 
 
   Summit is a biopharmaceutical company focused on the discovery, 
development and commercialisation of novel medicines for indications for 
which there are no existing or only inadequate therapies. Summit is 
conducting clinical programmes focused on the genetic disease Duchenne 
muscular dystrophy and the infectious disease C. difficile infection. 
Further information is available at www.summitplc.com and Summit can be 
followed on Twitter (@summitplc). 
 
   Contacts 
 
 
 
 
Summit 
 Glyn Edwards / Richard Pye (UK office)                  Tel: +44 (0)1235 443 951 
 Erik Ostrowski / Michelle Avery (US office)             +1 617 225 4455 
Cairn Financial Advisers LLP (Nominated Adviser)       Tel: +44 (0)20 7213 0880 
 Liam Murray / Tony Rawlinson 
N+1 Singer (Joint Broker)                              Tel: +44 (0)20 7496 3000 
 Aubrey Powell / Jen Boorer 
Pamure Gordon (Joint Broker)                           Tel: +44 (0)20 7886 2500 
 Freddy Crossley / Duncan Monteith, Corporate Finance 
 Tom Salvesen, Corporate Broking 
 
MacDougall Biomedical Communications (US)              Tel: +1 781 235 3060 
 Karen Sharma                                           ksharma@macbiocom.com 
Consilium Strategic Communications (UK)                Tel: +44 (0)20 3709 5700 
 Mary-Jane Elliott / Sue Stuart /                       summit@consilium-comms.com 
 Jessica Hodgson / Philippa Gardner 
 
 
   -END- 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Summit Therapeutics plc via Globenewswire 
 
 
  http://www.summitplc.com/ 
 

(END) Dow Jones Newswires

November 16, 2017 02:00 ET (07:00 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.

1 Year Summit Therapeutics Chart

1 Year Summit Therapeutics Chart

1 Month Summit Therapeutics Chart

1 Month Summit Therapeutics Chart

Your Recent History

Delayed Upgrade Clock